» Articles » PMID: 28534009

Genomic Insight into Mechanisms of Reversion of Antibiotic Resistance in Multidrug Resistant Induced by a Nanomolecular Iodine-Containing Complex FS-1

Overview
Date 2017 May 24
PMID 28534009
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Drug induced reversion of antibiotic resistance is a promising way to combat multidrug resistant infections. However, lacking knowledge of mechanisms of drug resistance reversion impedes employing this approach in medicinal therapies. Induction of antibiotic resistance reversion by a new anti-tuberculosis drug FS-1 has been reported. FS-1 was used in this work in combination with standard anti-tuberculosis antibiotics in an experiment on laboratory guinea pigs infected with an extensively drug resistant (XDR) strain SCAID 187.0. During the experimental trial, genetic changes in the population were analyzed by sequencing of isolates followed by variant calling. In total 11 isolates obtained from different groups of infected animals at different stages of disease development and treatment were sequenced. It was found that despite the selective pressure of antibiotics, FS-1 caused a counter-selection of drug resistant variants that speeded up the recovery of the infected animals from XDR tuberculosis. Drug resistance mutations reported in the genome of the initial strain remained intact in more sensitive isolates obtained in this experiment. Variant calling in the sequenced genomes revealed that the drug resistance reversion could be associated with a general increase in genetic heterogeneity of the population of . Accumulation of mutations in PpsA and PpsE subunits of phenolpthiocerol polyketide synthase was observed in the isolates treated with FS-1 that may indicate an increase of persisting variants in the population. It was hypothesized that FS-1 caused an active counter-selection of drug resistant variants from the population by aggravating the cumulated fitness cost of the drug resistance mutations. Action of FS-1 on drug resistant bacteria exemplified the theoretically predicted induced synergy mechanism of drug resistance reversion. An experimental model to study the drug resistance reversion phenomenon is hereby introduced.

Citing Articles

Synthesis, physicochemical properties and antimicrobial activity of a di-aminopropionic acid hydrogen tri-iodide coordination compound.

Turganbay S, Kenesheva S, Jumagaziyeva A, Ilin A, Askarova D, Azembayev A BMC Res Notes. 2024; 17(1):384.

PMID: 39722003 PMC: 11670392. DOI: 10.1186/s13104-024-07052-8.


Universal Lineage-Independent Markers of Multidrug Resistance in .

Hlanze H, Mutshembele A, Reva O Microorganisms. 2024; 12(7).

PMID: 39065108 PMC: 11278869. DOI: 10.3390/microorganisms12071340.


The Effect of Three Complexes of Iodine with Amino Acids on Gene Expression of Model Antibiotic Resistant Microorganisms ATCC BAA-196 and ATCC BAA-39.

Kenesheva S, Taukobong S, Shilov S, Kuznetsova T, Jumagaziyeva A, Karpenyuk T Microorganisms. 2023; 11(7).

PMID: 37512878 PMC: 10383335. DOI: 10.3390/microorganisms11071705.


Whole-Genome Sequence-Based Characterization of Pre-XDR Clinical Isolates Collected in Kazakhstan.

Daniyarov A, Akhmetova A, Rakhimova S, Abilova Z, Yerezhepov D, Chingissova L Diagnostics (Basel). 2023; 13(12).

PMID: 37370900 PMC: 10296843. DOI: 10.3390/diagnostics13122005.


Prediction of drug resistance by Sanger sequencing of Mycobacterium tuberculosis complex strains isolated from multidrug resistant tuberculosis suspect patients in Ethiopia.

Mesfin E, Merker M, Beyene D, Tesfaye A, Shuaib Y, Addise D PLoS One. 2022; 17(8):e0271508.

PMID: 35930613 PMC: 9355188. DOI: 10.1371/journal.pone.0271508.


References
1.
Gagneux S, Long C, Small P, Van T, Schoolnik G, Bohannan B . The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006; 312(5782):1944-6. DOI: 10.1126/science.1124410. View

2.
Morens D, Folkers G, Fauci A . The challenge of emerging and re-emerging infectious diseases. Nature. 2004; 430(6996):242-9. PMC: 7094993. DOI: 10.1038/nature02759. View

3.
Sreevatsan S, Stockbauer K, Pan X, Kreiswirth B, Moghazeh S, Jacobs Jr W . Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother. 1997; 41(8):1677-81. PMC: 163984. DOI: 10.1128/AAC.41.8.1677. View

4.
Pietersen E, Ignatius E, Streicher E, Mastrapa B, Padanilam X, Pooran A . Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 2014; 383(9924):1230-9. DOI: 10.1016/S0140-6736(13)62675-6. View

5.
Zager E, McNerney R . Multidrug-resistant tuberculosis. BMC Infect Dis. 2008; 8:10. PMC: 2241599. DOI: 10.1186/1471-2334-8-10. View